Tim Wartewig
About Tim Wartewig
Tim Wartewig is a Physician Scientist Postdoctoral Researcher currently working at the Cancer Research Institute as a CRI Irvington Fellow since 2021. He has a strong academic background in Mathematics, Computer Science, Oncology, and Cancer Biology, and has made significant contributions to the field of immunology through his research on T-cell lymphomas and immune cell signaling pathways.
Current Position at Cancer Research Institute
Tim Wartewig serves as a CRI Irvington Fellow at the Cancer Research Institute (CRI) since 2021. His role as a Physician Scientist Postdoctoral Researcher involves conducting advanced research in the field of cancer immunology. His work focuses on forward genomic in vivo screens aimed at deciphering immune cell signaling pathways and their functionality. Wartewig's research contributes to understanding the complex interactions between immune cells and tumors, with the goal of enhancing anti-tumor immunity.
Education and Academic Background
Tim Wartewig completed his education at Technische Universität München, where he studied Mathematics and Computer Science, earning a Diploma equivalent to a Master of Science from 2005 to 2011. He further pursued his studies in Oncology and Cancer Biology, achieving a Doctor of Philosophy (PhD) from 2014 to 2020. Additionally, he obtained a Bachelor of Science (BS) in Mathematics and Computer Science through the TopMath program from 2007 to 2009. He also earned a Doctor of Medicine (MD) from 2011 to 2019.
Previous Research Experience
Prior to his current position, Tim Wartewig worked at Klinikum rechts der Isar in Munich, Bavaria, Germany, where he held the roles of Resident Laboratory Medicine from 2020 to 2021 and MD-PhD student from 2014 to 2020. His research during this time included significant findings on T-cell lymphomas, which were validated in two independent phase II clinical trials, influencing clinical care standards. His work has contributed to advancements in understanding T-cell biology in the context of cancer.
Published Research Contributions
Tim Wartewig developed a novel conceptual framework for the inhibitory PD-1 receptor, identifying it as a major tumor suppressor in the T-cell lineage. This research was published in the journal Nature in 2017. His findings have implications for cancer treatment strategies, particularly in enhancing the efficacy of immunotherapies targeting T-cell responses.
Internship Experience
Earlier in his career, Tim Wartewig gained practical experience through internships at HypoVereinsbank - UniCredit - Deutschland in 2011 and Allianz Global Investors in 2010. These internships provided him with exposure to the financial sector, complementing his scientific training and broadening his skill set.